In addition, the effects of CVC on liver fibrosis are related to the reduction of inflammation-related biomarkers, such as IL-6, IL-1β, etc., which indicates that CVC is a great potential anti-liver fibrosis candidate drug because inflammation is one of the important factors causing liver fibrosis (Friedman et al., 2016). The gene discussed is IL6; the disease is Hepatic fibrosis.